Help us fund research to slow, stop and reverse Parkinson’s
Now in its 8th year, the International Linked Clinical Trials programme is a collaboration between the Van Andel Institute and The Cure Parkinson's Trust designed to move potentially disease-modifying repurposed drugs quickly into clinical trials for Parkinson's... Read more
We fund and support clinical trials which seek to slow, stop or reverse Parkinson's. Find out about these trials - part of our Linked Clinical trials programme developed in conjunction with the Van Andel Institute - which are recruiting... Read more
The Cure Parkinson’s Trust (CPT) funds work to slow, stop or reverse Parkinson’s (PD). We fund both clinical trials and preclinical work which seeks to open up new avenues in the search for a cure - all of which have the potential to make a real difference to the lives of people living with Parkinson's.
CPT was founded by four people with Parkinson’s which means that patient experience informs all our work. If you would like to help us drive forward our research, please donate today - thank you.
Our international Linked Clinical Trials initiative (LCT) identifies potential new treatments to slow, stop or reverse Parkinson’s disease by 'repurposing' or repositioning drugs that are approved to treat other conditions. Read more
Regenerative medicine offers hope for a fundamental cure and continues to make substantial progress in Parkinson's. Read more
Our Linked Clinical Trials committee annually assesses favourable drugs which, in studies, have demonstrated putative disease-modifying action in Parkinson's - we are actively committed to bringing these to trial. Read more
When diagnosed, people with Parkinson’s have often had the disease for years and have lost over half of the dopamine producing cells in their brain. Now scientists are searching for a way to replace these nerve cells. Read more
We are partnered with the Van Andel Research Institute (VARI) - an independent nonprofit biomedical research and science education organisation - for our Linked Clinical Trials programme. Read more